<p>Blade Air Mobility, Inc. ((SRTA)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF 人工智能分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> 人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> 人工智能分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>Blade Air Mobility, Inc. 最近的财报电话会议描绘了一个总体积极的局面，显著的收入增长和战略交易为未来的成功奠定了基础。公司报告了强劲的利润率和良好的现金流生成前景。然而，Joby 交易对股价的影响以及持续的法律问题也被提及。</p>
<h2>收入增长与盈利能力</h2>
<p>公司实现了令人印象深刻的同比收入增长 29%，不包括 Keystone 收购。这一增长伴随着创纪录的调整后 EBITDA 表现，增长了 80%。医疗部门的调整后 EBITDA 利润率也显著改善，在 2025 年第三季度达到了 15% 以上，而去年为 10.8%。</p>
<h2>战略交易与品牌重塑</h2>
<p>Blade Air Mobility 完成了两项重大交易：剥离其乘客业务和收购 Keystone Perfusion。这些举措是更广泛品牌重塑努力的一部分，导致公司更名为 Strata Critical Medical，并采用新的股票代码 SRTA。</p>
<h2>积极的自由现金流</h2>
<p>公司报告了来自持续运营的积极自由现金流，并预计将保持这一趋势。这是公司财务健康和维持增长能力的强有力指标。</p>
<h2>新旧服务的强劲表现</h2>
<p>来自器官移植服务的收入同比增长超过一倍，展示了公司在新旧服务方面的实力。此外，在第三季度末新增了一位器官物流客户，进一步增强了增长前景。</p>
<h2>Joby 交易对股价的影响</h2>
<p>财报电话会议强调了 Joby 交易中现金收益的 1000 万美元差异，归因于在测量期间 Joby 股价的显著下跌。这被视为影响财务结果的挑战。</p>
<h2>针对持续诉讼的法律准备金</h2>
<p>针对公司上市交易的持续诉讼，已计提法律准备金，如 SEC 文件中披露的。这突显了公司正在应对的持续法律挑战。</p>
<h2>前瞻性指导</h2>
<p>在财报电话会议中，Strata Critical Medical 提供了强劲的指导，预测不包括 Keystone 收购的同比收入增长 29%。公司还报告了调整后 EBITDA 表现创历史新高，同比增长 80%。尽管移植量季节性下降，但收入环比增长了 3%。公司将 2025 年的收入指导上调至 1.85 亿至 1.95 亿美元，并重申调整后 EBITDA 指导范围为 1300 万至 1400 万美元，预计医疗部门的调整后 EBITDA 利润率将在 2025 年第四季度有所提高。</p>
<p>总之，Blade Air Mobility 现在的 Strata Critical Medical 在财报电话会议中表现总体积极，强调了显著的收入增长和战略交易。尽管提到了 Joby 交易影响和持续法律问题等挑战，但公司的强劲财务表现和前瞻性指导表明了一个光明的未来。</p>

BLDE

<p>Blade Air Mobility, Inc.（现为 Strata Critical Medical）举行了第三季度财报电话会议，报告了 29% 的年同比收入增长和 80% 的调整后 EBITDA 增长。公司完成了重要交易，包括剥离其乘客业务和收购 Keystone Perfusion。尽管 Joby 交易对股价造成了影响，并且面临持续的法律问题，但前景依然乐观，2025 年的收入指引上调至 1.85 亿至 1.95 亿美元，并预计现金流和盈利能力将改善</p>

<p>Blade Air Mobility, Inc. ((SRTA)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Blade Air Mobility, Inc. ((SRTA)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF 人工智能分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> 人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> 人工智能分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>The recent earnings call for Blade Air Mobility, Inc. painted a largely positive picture, with significant revenue growth and strategic transactions setting the stage for future success. The company reported strong profit margins and a promising outlook for cash flow generation. However, challenges such as the impact of the Joby transaction on stock price and ongoing legal issues were also acknowledged.</p>
<div class="lb-trans"><p>Blade Air Mobility, Inc. 最近的财报电话会议描绘了一个总体积极的局面，显著的收入增长和战略交易为未来的成功奠定了基础。公司报告了强劲的利润率和良好的现金流生成前景。然而，Joby 交易对股价的影响以及持续的法律问题也被提及。</p>
</div><h2>Revenue Growth and Profitability</h2>
<div class="lb-trans"><h2>收入增长与盈利能力</h2>
</div><p>The company experienced impressive year-over-year revenue growth of 29%, excluding the Keystone acquisition. This was complemented by a record segment adjusted EBITDA performance, which saw an 80% increase. The medical segment adjusted EBITDA margin also improved significantly, reaching over 15% in Q3 2025, up from 10.8% the previous year.</p>
<div class="lb-trans"><p>公司实现了令人印象深刻的同比收入增长 29%，不包括 Keystone 收购。这一增长伴随着创纪录的调整后 EBITDA 表现，增长了 80%。医疗部门的调整后 EBITDA 利润率也显著改善，在 2025 年第三季度达到了 15% 以上，而去年为 10.8%。</p>
</div><h2>Strategic Transactions and Rebranding</h2>
<div class="lb-trans"><h2>战略交易与品牌重塑</h2>
</div><p>Blade Air Mobility completed two major transactions: the divestiture of its passenger business and the acquisition of Keystone Perfusion. These moves were part of a broader rebranding effort, resulting in the company being renamed Strata Critical Medical and adopting a new ticker symbol, SRTA.</p>
<div class="lb-trans"><p>Blade Air Mobility 完成了两项重大交易：剥离其乘客业务和收购 Keystone Perfusion。这些举措是更广泛品牌重塑努力的一部分，导致公司更名为 Strata Critical Medical，并采用新的股票代码 SRTA。</p>
</div><h2>Positive Free Cash Flow</h2>
<div class="lb-trans"><h2>积极的自由现金流</h2>
</div><p>The company reported positive free cash flow from continuing operations, with expectations to maintain this trend moving forward. This is a strong indicator of the company’s financial health and its ability to sustain growth.</p>
<div class="lb-trans"><p>公司报告了来自持续运营的积极自由现金流，并预计将保持这一趋势。这是公司财务健康和维持增长能力的强有力指标。</p>
</div><h2>Strong Performance in New and Existing Services</h2>
<div class="lb-trans"><h2>新旧服务的强劲表现</h2>
</div><p>Revenue from organ placement services more than doubled year-over-year, showcasing the company’s strength in both new and existing services. Additionally, a new organ logistics customer was added late in Q3, further bolstering growth prospects.</p>
<div class="lb-trans"><p>来自器官移植服务的收入同比增长超过一倍，展示了公司在新旧服务方面的实力。此外，在第三季度末新增了一位器官物流客户，进一步增强了增长前景。</p>
</div><h2>Joby Transaction Stock Price Impact</h2>
<div class="lb-trans"><h2>Joby 交易对股价的影响</h2>
</div><p>The earnings call highlighted a $10 million difference in cash proceeds from the Joby transaction, attributed to a significant decline in Joby’s stock price during the measurement period. This was noted as a challenge impacting financial outcomes.</p>
<div class="lb-trans"><p>财报电话会议强调了 Joby 交易中现金收益的 1000 万美元差异，归因于在测量期间 Joby 股价的显著下跌。这被视为影响财务结果的挑战。</p>
</div><h2>Legal Provision for Ongoing Litigation</h2>
<div class="lb-trans"><h2>针对持续诉讼的法律准备金</h2>
</div><p>A legal provision was booked related to ongoing litigation from the company’s go-public transaction, as disclosed in SEC filings. This highlights ongoing legal challenges that the company is addressing.</p>
<div class="lb-trans"><p>针对公司上市交易的持续诉讼，已计提法律准备金，如 SEC 文件中披露的。这突显了公司正在应对的持续法律挑战。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>During the earnings call, Strata Critical Medical provided robust guidance, forecasting a significant year-over-year revenue growth of 29%, excluding the Keystone acquisition. The company also reported an all-time high in segment adjusted EBITDA performance, with an 80% increase year-over-year. Despite a seasonal decline in transplant volumes, revenue rose 3% sequentially. The company raised its 2025 revenue guidance to $185-$195 million and reaffirmed its adjusted EBITDA guidance range of $13-$14 million, with expectations of increased medical segment adjusted EBITDA margins in Q4 2025.</p>
<div class="lb-trans"><p>在财报电话会议中，Strata Critical Medical 提供了强劲的指导，预测不包括 Keystone 收购的同比收入增长 29%。公司还报告了调整后 EBITDA 表现创历史新高，同比增长 80%。尽管移植量季节性下降，但收入环比增长了 3%。公司将 2025 年的收入指导上调至 1.85 亿至 1.95 亿美元，并重申调整后 EBITDA 指导范围为 1300 万至 1400 万美元，预计医疗部门的调整后 EBITDA 利润率将在 2025 年第四季度有所提高。</p>
</div><p>In conclusion, Blade Air Mobility, now Strata Critical Medical, delivered a largely positive earnings call, underscored by significant revenue growth and strategic transactions. While challenges such as the Joby transaction impact and ongoing legal issues were noted, the company’s strong financial performance and forward-looking guidance suggest a promising future.</p>
<div class="lb-trans"><p>总之，Blade Air Mobility 现在的 Strata Critical Medical 在财报电话会议中表现总体积极，强调了显著的收入增长和战略交易。尽管提到了 Joby 交易影响和持续法律问题等挑战，但公司的强劲财务表现和前瞻性指导表明了一个光明的未来。</p>
</div>

Blade Air Mobility 的财报电话会议：增长与战略行动